FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, finding sufficient shortcomings in post-market monitoring and pre-market notification to warrant a warning letter.
J&J and subsidiary McNeil Consumer Healthcare say they have come a long way in improving management of OTC pharma...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?